Study Group for Urogenital Diseases, Italy Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2017
NCT03493997
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Gruppo di Studio per le Malattie Urogenitali | Study Group for Urogenital Diseases, Italy

Active Ingredients

Drugs in Phase 2 Trials (1)

hyaluronic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cystitis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1